lutetium Lu 177 DOTA-tetulomab

{
  "id": "MLC-T-ONC-014913",
  "term": "lutetium Lu 177 DOTA-tetulomab",
  "field": "Oncology and biomedicine",
  "definition": "A radioimmunoconjugate, which consists of a monoclonal antibody against the cell-surface antigen CD37 covalently linked, via the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. The antibody moiety of lutetium Lu 177 DOTA-tetulomab binds to CD37 on tumor B-cells. Upon internalization, the radioisotope moiety delivers a cytotoxic dose of beta radiation to CD37-expressing tumor cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies.",
  "synonyms": [
    "177Lu-Dota-tetulomab",
    "177Lu-HH1",
    "177Lu-DOTA-HH1"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lutetium-lu-177-dota-tetulomab/"
}